# US 2010/0076195 A1 · Purification of montelukast

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0076195 A1
- Document ID: US20100076195A1
- Status: Published application
- Kind: A1
- Application number: 12/546,203
- Filed: 2009-08-24
- Published: 2010-03-25
- Earliest claimed: 2005-07-05
- Assignees: Teva Pharmaceutical Industries Ltd.; Teva Pharmaceuticals USA, Inc.
- Inventors: Greta STERIMBAUM; Evgeny SHAPIRO; Kobi CHEN
- Web page: https://patentgrep.com/patent/US20100076195A1

## CPC

- C07D 215/18: Halogen atoms or nitro radicals
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods of purifying montelukast, a new isolated impurity of montelukast, method for its isolation, and method of using montelukast impurity as a reference marker and a reference standard.

## Claims

### Claim at position 1

1-3. (canceled)

### Claim 4

An isolated impurity, [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-propenyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (MLK-D) of the following structure:

### Claim at position 3

5-16. (canceled)
